Monacef (Cefuroxime Sodium)

Cefuroxime sodium, the active ingredient in Monacef, is a second‑generation cephalosporin presented as a sterile injectable solution for intramuscular and intravenous administration. It is employed to treat a broad spectrum of bacterial infections, such as community‑acquired pneumonia, acute bronchitis, uncomplicated urinary tract infections, cellulitis, wound infections, sinusitis and otitis media, in adult and pediatric patients as appropriate and may be used in hospital or outpatient settings.

GNH USA supplies Monacef as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cefuroxime sodium is a second‑generation cephalosporin antibiotic used to treat infections caused by susceptible bacteria in various organ systems. - Respiratory tract infections: effective for community‑acquired pneumonia, acute bronchitis and exacerbations of chronic bronchitis caused by susceptible organisms. - Urinary tract infections: treats uncomplicated cystitis and pyelonephritis when caused by cefuroxime‑sensitive bacteria. - Skin and soft‑tissue infections: used for cellulitis, wound infections and abscesses due to susceptible Gram‑positive and Gram‑negative pathogens. - Sinusitis: indicated for acute bacterial sinusitis caused by susceptible strains. - Otitis media: employed in the management of middle‑ear infections in children and adults when pathogens are susceptible.

Cefuroxime sodium may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate nausea reported during or after infusion. - Diarrhea: loose stools, sometimes watery, occurring within days of treatment. - Injection site pain: local discomfort, erythema or swelling at the intramuscular or intravenous site. - Rash: transient maculopapular skin eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening hypersensitivity reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: severe colitis that may develop during or after therapy. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions with mucosal involvement. - Hemolytic anemia: immune‑mediated destruction of red blood cells.

When prescribing cefuroxime sodium, clinicians should consider several precautionary measures to minimise risk and ensure optimal therapy. - Renal function: assess creatinine clearance and adjust dose in patients with impaired renal function. - Allergy history: avoid use in individuals with known hypersensitivity to cephalosporins or penicillins. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk to the fetus or infant. - Drug interactions: review concomitant medications that may affect renal excretion or increase toxicity. - Administration technique: use aseptic technique, dilute according to label instructions, and monitor for infusion‑related reactions. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cefuroxime sodium can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Probenecid: reduces renal excretion of cefuroxime, increasing serum concentrations and risk of toxicity. - Live bacterial vaccines: concurrent use may diminish vaccine efficacy. - Nephrotoxic agents (e.g., aminoglycosides, vancomycin): combined use heightens the risk of renal impairment.

Moderate Interactions (Monitor Closely): - Warfarin: cefuroxime may potentiate anticoagulant effect, requiring INR monitoring. - Diuretics: may affect renal clearance of cefuroxime, necessitating dose adjustment.